Severity of disease

[키워드] Abstract activities activity acute respiratory distress acute respiratory distress syndrome adaptive Administered Adult patient Adult patients Analysis antiviral efficacy assigned Bacterial infection Belgium block Breastfeeding Chronic kidney disease clinical clinical benefit Clinical efficacy clinical evidence Clinical research clinical status Combination Commission computer-generated conducted control group Controlled trial COVID-19 criteria death development discharged distribution elevated elevated liver enzymes eligible enrolled Europe European evaluate evidence of exclusion criteria extracorporeal membrane oxygenation followed by France French group Health care hepatorenal syndrome high flow oxygen devices hospital hospitalised Hydroxychloroquine Inclusion indication Innovation intention-to-treat population interferon interferon beta Interferon beta-1a intravenous intravenous infusion Invasive mechanical ventilation investigators Kidney disease laboratory-confirmed SARS-CoV-2 infection limitation liver enzymes Lopinavir Lopinavir-ritonavir Luxembourg material Ministry of Health modified intention-to-treat multicentre no significant difference non-invasive ventilation not significant Occurrence Odds ratio once daily one health Open-label Ordinal Scale oxygen oxygen supplementation oxygen support participant Patient Phase 3 Pneumonia Portugal Pregnancy Primary outcome random assignment randomisation randomised Randomly receive Regional Registered Remdesivir required requiring supplemental oxygen respiratory distress ribavirin Ritonavir Safety SARS-CoV-2 SARS-COV-2 infection Secondary outcomes Serious Adverse Event Serious Adverse Events seven-point ordinal scale Severity of disease Sponsor Standard of care stratified supplemental oxygen Support symptomatic syndrome the WHO translation Treatment treatment group treatment groups Trial Tumor union ventilator were excluded WHO ordinal scale with COVID-19
[DOI] 10.1016/S1473-3099(21)00485-0 PMC 바로가기 [Article Type] Clinical Trial